US2006153832A1PendingUtilityA1

Immunomodulating polymers

Assignee: BRIGHAM & WOMENS HOSPITALPriority: Apr 2, 1999Filed: Mar 21, 2006Published: Jul 13, 2006
Est. expiryApr 2, 2019(expired)· nominal 20-yr term from priority
A61K 35/742A61K 45/06A61K 38/00A61K 31/715A61K 31/785
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and products for inducing IL-2 secretion, inducing IL-10 secretion, activating T cells, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation are provided. The methods of the invention are accomplished using an immunomodulator which is a polymer having at least two repeating charge motifs separated by at least a certain minimum distance.

Claims

exact text as granted — not AI-modified
1 . A method for treating a subject having a disorder characterized by an inappropriate IgG antibody response to specific antigen comprising: 
 administering to a subject having a disorder characterized by an inappropriate IgG antibody a pharmaceutical preparation containing an effective amount for suppressing IgG antibody response to specific antigen of a polymer of less than 50 kilodaltons having at least two repeating charge motifs, wherein the repeating charge motif is composed of a positively charged free amino moiety and a negative charge, wherein the positively charged free amino moieties of the at least two repeating charge motifs are separated by a distance of at least 32 Å, wherein when the polymer is a polypeptide the polymer does not consist of lysine (K), glutamic acid (E), alanine (A), and tyrosine (Y) residues in a relative molar ratio of 3-7 parts of K to 1-3 parts of E to 4-7 parts of A, to 0.5-2 parts of Y, and wherein the subject is not preparing to undergo surgery.    
     
     
         2 . The method of 1, wherein the pharmaceutical preparation is administered to the subject once a day.  
     
     
         3 . The method of 1, wherein the pharmaceutical preparation has a positive to negative charge ratio of 1:1.

Join the waitlist — get patent alerts

Track US2006153832A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.